Reflux inhibitors: a new approach for GERD?

Current Opinion in Pharmacology

Volumn 8, Issue 6, 2008, Pages 685-689

  Boeckxstaens, Guy E ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; ANTACID AGENT; ATROPINE; AZD 3355; AZD 9343; BACLOFEN; CANNABINOID DERIVATIVE; CANNABINOID RECEPTOR AGONIST; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DRONABINOL; GASTROINTESTINAL AGENT; GLUTAMATE RECEPTOR AGONIST; GLUTAMATE RECEPTOR ANTAGONIST; METABOTROPIC RECEPTOR 5 ANTAGONIST; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; MORPHINE; PROTON PUMP INHIBITOR; RILUZOLE; UNCLASSIFIED DRUG; XP 19986;

ADD ON THERAPY; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG CHOICE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; GASTROESOPHAGEAL REFLUX; HIATUS HERNIA; HUMAN; LOWER ESOPHAGUS SPHINCTER PRESSURE; MECHANORECEPTOR; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SMOOTH MUSCLE CONTRACTION; SMOOTH MUSCLE RELAXATION; SOMNOLENCE; SYMPTOM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; BACLOFEN; ESOPHAGEAL SPHINCTER, LOWER; ESOPHAGITIS, PEPTIC; GASTROESOPHAGEAL REFLUX; HUMANS; MUSCLE RELAXANTS, CENTRAL; MUSCLE RELAXATION; PROTON PUMP INHIBITORS;

EID: 55649117966     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2008.08.005     Document Type: Review

References (50)

1. Vakil N., Van Zanten S.V., Kahrilas P., Dent J., and Jones R. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 101 (2006) 1900-1920
2. Chiba N., De Gara C.J., Wilkinson J.M., and Hunt R.H. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 112 (1997) 1798-1810
3. Klinkenberg-Knol E.C., Nelis F., Dent J., Snel P., Mitchell B., Prichard P., Lloyd D., Havu N., Frame M.H., Roman J., and Walan A. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 118 (2000) 661-669
4. Fass R. Persistent heartburn in a patient on proton-pump inhibitor. Clin Gastroenterol Hepatol 6 (2008) 393-400
5. Ang D., Sifrim D., and Tack J. Mechanisms of heartburn. Nat Clin Pract Gastroenterol Hepatol 5 (2008) 383-392
6. Vela M.F., Camacho-Lobato L., Srinivasan R., Tutuian R., Katz P.O., and Castell D.O. Simultaneous intraesophageal impedance and pH measurement of acid and nonacid gastroesophageal reflux: effect of omeprazole. Gastroenterology 120 (2001) 1599-1606. Study demonstrating that acid inhibition with a PPI reduces acid exposure, but the number of reflux episodes measured by impedance remains unaffected.
7. Hirsch D.P., Tytgat G.N., and Boeckxstaens G.E. Transient lower oesophageal sphincter relaxations-a pharmacological target for gastro-oesophageal reflux disease?. Aliment Pharmacol Ther 16 (2002) 17-26
8. Boeckxstaens G.E. The lower oesophageal sphincter. Neurogastroenterol Motil 17 Suppl. 1 (2005) 13-21
9. Kahrilas P.J., Dodds W.J., Hogan W.J., Kern M., Arndorfer R.C., and Reece A. Esophageal peristaltic dysfunction in peptic esophagitis. Gastroenterology 91 (1986) 897-904
10. Dodds W.J., Dent J., Hogan W.J., Helm J.F., Hauser R., Patel G.K., and Egide M.S. Mechanisms of gastroesophageal reflux in patients with reflux esophagitis. N Engl J Med 307 (1982) 1547-1552. This study revealed transient relaxation of the lower esophageal sphincter as new and important mechanism underlying reflux and has set the stage for reflux inhibitors as potential treatment for GERD.
11. Holloway R.H., Penagini R., and Ireland A.C. Criteria for objective definition of transient lower esophageal sphincter relaxation. Am J Physiol 268 (1995) G128-G133
12. Mittal R.K., and Fisher M.J. Electrical and mechanical inhibition of the crural diaphragm during transient relaxation of the lower esophageal sphincter. Gastroenterology 99 (1990) 1265-1268
13. Babaei A., Bhargava V., Korsapati H., Zheng W.H., and Mittal R.K. A unique longitudinal muscle contraction pattern associated with transient lower esophageal sphincter relaxation. Gastroenterology 134 (2008) 1322-1331
14. Mittal R.K., and McCallum R.W. Characteristics of transient lower esophageal sphincter relaxation in humans. Am J Physiol 252 (1987) G636-G641
15. Kahrilas P.J. The role of hiatus hernia in GERD. Yale J Biol Med 72 (1999) 101-111
16. Mittal R.K., and Balaban D.H. The esophagogastric junction. N Engl J Med 336 (1997) 924-932. Very elegant review on the physiology and pathophysiology of the esophagogastric junction.
17. Kahrilas P.J., Lin S., Chen J., and Manka M. The effect of hiatus hernia on gastro-oesophageal junction pressure. Gut 44 (1999) 476-482
18. Sloan S., Rademaker A.W., and Kahrilas P.J. Determinants of gastroesophageal junction incompetence: hiatal hernia, lower esophageal sphincter, or both?. Ann Intern Med 117 (1992) 977-982
19. van Herwaarden M.A., Samsom M., and Smout A.J. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 119 (2000) 1439-1446
20. Mittal R.K., Holloway R., and Dent J. Effect of atropine on the frequency of reflux and transient lower esophageal sphincter relaxation in normal subjects. Gastroenterology 109 (1995) 1547-1554. Key reference demonstrating that TLESRs can be inhibited by pharmacological intervention, leading to a reduction of reflux, even in the absence of LES pressure.
21. Vela M.F., Tutuian R., Katz P.O., and Castell D.O. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 17 (2003) 243-251. Important study showing that inhibition of TLESRs, in contrast to PPIs, is capable of reducing both acid and non-acid reflux.
22. B receptor activation in humans reduces TLESRs.
23. Ciccaglione A.F., and Marzio L. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease. Gut 52 (2003) 464-470
24. van Herwaarden M.A., Samsom M., Rydholm H., and Smout A.J. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther 16 (2002) 1655-1662
25. Cange L., Johnsson E., Rydholm H., Lehmann A., Finizia C., Lundell L., and Ruth M. Baclofen-mediated gastro-oesophageal acid reflux control in patients with established reflux disease. Aliment Pharmacol Ther 16 (2002) 869-873
26. Koek G.H., Sifrim D., Lerut T., Janssens J., and Tack J. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors. Gut 52 (2003) 1397-1402. This study clearly demonstrates that baclofen reduces duodeno-gastro-esophageal reflux in patients on PPIs, illustrating that reflux inhibitors have the potential to target PPI resistant reflux.
27. Zhang Q., Lehmann A., Rigda R., Dent J., and Holloway R.H. Control of transient lower oesophageal sphincter relaxations and reflux by the GABA(B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 50 (2002) 19-24
28. Beaumont H., Jonsson-Rylander A.C., Carlsson K., Pierrou S., Ahlefelt M., Branden L., Jensen J., Boeckxstaens G.E., and Lehmann A. The role of GABA(A) receptors in the control of transient lower oesophageal sphincter relaxations in the dog. Br J Pharmacol 153 (2008) 1195-1202
29. Boeckxstaens G.E., Hirsch D.P., Fakhry N., Holloway R.H., D'Amato M., and Tytgat G.N. Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension. Am J Gastroenterol 93 (1998) 1823-1828
30. Penagini R., and Bianchi P.A. Effect of morphine on gastroesophageal reflux and transient lower esophageal sphincter relaxation. Gastroenterology 113 (1997) 409-414
31. Hirsch D.P., Tytgat G.N., and Boeckxstaens G.E. Is glutamate involved in transient lower esophageal sphincter relaxations?. Dig Dis Sci 47 (2002) 661-666
32. Lehmann A., Blackshaw L.A., Branden L., Carlsson A., Jensen J., Nygren E., and Smid S.D. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 123 (2002) 1129-1134
33. Frisby C.L., Mattsson J.P., Jensen J.M., Lehmann A., Dent J., and Blackshaw L.A. Inhibition of transient lower esophageal sphincter relaxation and gastroesophageal reflux by metabotropic glutamate receptor ligands. Gastroenterology 129 (2005) 995-1004. Very elegant study demonstrating the effect of several mGluR ligands on TLESRs.
34. Jensen J., Lehmann A., Uvebrant A., Carlsson A., Jerndal G., Nilsson K., Frisby C., Blackshaw L.A., and Mattsson J.P. Transient lower esophageal sphincter relaxations in dogs are inhibited by a metabotropic glutamate receptor 5 antagonist. Eur J Pharmacol 519 (2005) 154-157
35. Hirsch D.P., Holloway R.H., Tytgat G.N., and Boeckxstaens G.E. Involvement of nitric oxide in human transient lower esophageal sphincter relaxations and esophageal primary peristalsis. Gastroenterology 115 (1998) 1374-1380
36. Lehmann A., Antonsson M., Bremner-Danielsen M., Flardh M., Hansson-Branden L., and Karrberg L. Activation of the GABA(B) receptor inhibits transient lower esophageal sphincter relaxations in dogs. Gastroenterology 117 (1999) 1147-1154
37. McDermott C.M., Abrahams T.P., Partosoedarso E., Hyland N., Ekstrand J., Monroe M., and Hornby P.J. Site of action of GABA(B) receptor for vagal motor control of the lower esophageal sphincter in ferrets and rats. Gastroenterology 120 (2001) 1749-1762
38. Grossi L., Spezzaferro M., Sacco L.F., and Marzio L. Effect of baclofen on oesophageal motility and transient lower oesophageal sphincter relaxations in GORD patients: a 48-h manometric study. Neurogastroenterol Motil 20 (2008) 760-766
39. Castell D., Gerson L.B., Hirota W.K., Reilley S.F., Hila A., Agrawal A., Lal R., and Huff J. R-Baclofen prodrug Xp19986 decreases reflux episodes and is well tolerated in GERD patients. Gastroenterology 132 (2008) A-486
40. Lehmann A., Elebring T., Jensen J., Mattsson J.P., Nilsson K., Saransaari P., and von Unge S. In vivo and in vitro characterization of AZD9343, a novel GABAB receptor agonist and reflux inhibitor. Gastroenterology 134 (2008) A-131-A-132
41. Lehmann A., Branden L., Carlsson A., Elebring T., Jensen J., Mattsson J.P., Nilsson K.A., Uvebrant A., and von Unge S. AZD3355, a novel GABAB receptor agonist inhibits transient lower esophageal sphincter relaxation in the dog [abstract]. Gastroenterology 134 (2008) A-49-A-50
42. Boeckxstaens G.E., Beaumont H., Rydholm H., Ruth M., Lei A., Lehmann A., and Smout A.J. Effect of the GABAB receptor agonist on transient lower esophageal sphincter relaxations and acid reflux in healthy subjects: a phase I trial. Gastroenterology 134 (2008) A-126
43. Page A.J., Young R.L., Martin C.M., Umaerus M., O'Donnell T.A., Cooper N.J., Coldwell J.R., Hulander M., Mattsson J.P., Lehmann A., and Blackshaw L.A. Metabotropic glutamate receptors inhibit mechanosensitivity in vagal sensory neurons. Gastroenterology 128 (2005) 402-410
44. Lindstrom E., Brusberg M., Hughes P.A., Martin C.M., Brierley S.M., Phillis B.D., Martinsson R., Abrahamsson C., Larsson H., Martinez V., and Ashley B.L. Involvement of metabotropic glutamate 5 receptor in visceral pain. Pain 137 (2008) 295-305
45. Partosoedarso E.R., Abrahams T.P., Scullion R.T., Moerschbaecher J.M., and Hornby P.J. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 550 (2003) 149-158
46. Van S., Oland L.D., Ho W., Hillard C.J., Mackie K., Davison J.S., and Sharkey K.A. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 121 (2001) 767-774
47. Beaumont H, Jensen J, Carlsson A, Ruth M, Lehmann A, Boeckxstaens G: Effect of delta-9-tetra-hydrocannabinol, a cannabinoid receptor agonist on the triggering of TLESRs in dogs and healthy subjects. Brit J Pharmacol, in press.
48. Boeckxstaens G.E., and Tytgat G.N. More pathophysiologically oriented treatment of GORD?. Lancet 359 (2002) 1267-1268
49. Frazzoni M., De M.E., Grisendi A., and Savarino V. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression. Aliment Pharmacol Ther 16 (2002) 881-886
50. Gordon C., Kang J.Y., Neil P.J., and Maxwell J.D. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 20 (2004) 719-732